610 Medizin und Gesundheit
Refine
Year of publication
- 2016 (334) (remove)
Document Type
- Article (334) (remove)
Has Fulltext
- yes (334) (remove)
Is part of the Bibliography
- no (334)
Keywords
- Mitochondria (4)
- apoptosis (4)
- Apoptosis (3)
- Cancer (3)
- Gender (3)
- Germany (3)
- ROS (3)
- autophagy (3)
- cancer (3)
- cirrhosis (3)
- ABCB1 (2)
- Absorption (2)
- Acute leukemia (2)
- Aging (2)
- B-cell lymphoma (2)
- Borrelia (2)
- Calcium (2)
- Cell signalling (2)
- Cortex (2)
- CyberKnife robotic radiosurgery (2)
- Diabetes mellitus (2)
- Diagnostic markers (2)
- Experimental models of disease (2)
- HIV (2)
- Heart transplantation (2)
- Immunotherapy (2)
- Infection (2)
- Long-term care (2)
- MLL-r leukemia (2)
- NADPH oxidase (2)
- Pain (2)
- Patient blood management (2)
- Pneumonia (2)
- Preclinical research (2)
- Progranulin (2)
- Proteomics (2)
- Snakebite (2)
- Stereotactic body radiation therapy (2)
- Structural plasticity (2)
- VEGF (2)
- atrial fibrillation (2)
- breast cancer (2)
- caspase-8 (2)
- complementary and alternative medicine (2)
- development (2)
- diagnosis (2)
- epigenetics (2)
- glioblastoma (2)
- hepatitis C (2)
- human (2)
- immune response (2)
- liver transplantation (2)
- mitosis (2)
- particulate matter (2)
- renal cell carcinoma (2)
- surgery (2)
- ubiquitination (2)
- 11q23/MLL rearrangements (1)
- A/D transition (1)
- ABS (1)
- AGC kinase (1)
- AIH immunopathogenesis (1)
- APMPPE - acute posterior multifocal placoid pigment epitheliopathy (1)
- APP (1)
- Abdominal infections (1)
- Academic medicine (1)
- Access (1)
- Accessory olfactory system (1)
- Action Plan for Medication Safety (1)
- Acute calcolous cholecystitis (1)
- Acute myeloid leukemia (1)
- Addiction (1)
- Adolescents (1)
- Adverse events (1)
- Air traffic (1)
- All-trans retinoic acid (1)
- Allergic asthma (1)
- Allogeneic hematopoietic stem (1)
- Allogeneic stem cell transplantation (1)
- Altitude training (1)
- Ameloblastoma (1)
- Anaemia (1)
- Analgesia (1)
- Anatomy (1)
- Anemia (1)
- Angiogenesis (1)
- Anti platelet therapy (1)
- Anti-tumor immunity (1)
- Antibiotic (1)
- Antibiotic stewardship (1)
- Anticoagulation (1)
- Antimicrobial resistance (1)
- Antivenom (1)
- Apixaban (1)
- Appendectomy (1)
- Appendicitis (1)
- Arrhythmia/all (1)
- Ascites (1)
- Aspergillus fumigatus (1)
- Athena SWAN (1)
- Atherosclerosis (1)
- Atrial Fibrillation (1)
- Atrial fibrillation (1)
- Atxn2 (1)
- Aurora (1)
- Autologous stem cell transplantation (1)
- Automated Tube Potential Selection (1)
- Automatic Environmental Tobacco Smoke Emitter (1)
- Autophagy (1)
- Azan trichrome stain (1)
- B-cell non-Hodgkin lymphoma (1)
- BET inhibitors (1)
- BMC (1)
- BRD4 (1)
- Backpropagating action potential (1)
- Bacteria (1)
- Bacterial infection (1)
- Bacterial pathogenesis (1)
- Bariatric surgery (1)
- Becton Dickinson (1)
- Benefit (1)
- Bibliometric analysis (1)
- Biliary tree stones (1)
- Bioavailability (1)
- Biomedical engineering (1)
- Bisphosphonates (1)
- Bleeding Risk (1)
- Blood loss (1)
- Blood transfusion (1)
- Bone defect (1)
- Bone regeneration (1)
- Boswellia serrata (1)
- Boswellic acids (1)
- Brain injury (1)
- Breast cancer (1)
- Breech delivery (1)
- Bromodomänen (1)
- Bungarus niger (1)
- C. elegans (1)
- CA1 (1)
- CD95/Fas receptor (1)
- CDK inhibitor (1)
- CIK cells (1)
- CNS cancer (1)
- COBL (1)
- COPD (1)
- CRISPR/Cas9 (1)
- CT pulmonary angiography (1)
- CT radiation exposure (1)
- CUELA (1)
- CYBA/p22phox (1)
- CYP1A1 (1)
- Caco-2 cells (1)
- Call for action (1)
- Cancer Staging (1)
- Cancer detection (1)
- Capecitabine (1)
- Carbapenem-resistente Gram-negative Bakterien (CRGN) (1)
- Carbapenemasen (1)
- Cardiac (1)
- Cardiac output (1)
- Cardiology (1)
- Cardiomyocyte signaling pathways (1)
- Cardioprotection (1)
- Cardiovascular disease (1)
- Catch-up validation study (1)
- Catheter ablation (1)
- Cats (1)
- Cdk1/cyclin B1 (1)
- Celiac disease (1)
- Cell salvage (1)
- Cell therapy (1)
- Centers for Disease Control and Prevention (1)
- Cerebellum (1)
- Cerebral cortex (1)
- Cesarean delivery (1)
- Checkpoint inhibitor (1)
- Chemical modification (1)
- Chemiluminescence (1)
- Chemische Sonden (1)
- Chemorefractory advanced gastric cancer (1)
- Chemotherapy (1)
- Children (1)
- Chimerism (1)
- Cholecystectomy (1)
- Chondral Lesion (1)
- Chromosomal translocations (1)
- Chronic hepatitis (1)
- Chronic inflammation (1)
- Cigarettes (1)
- Claudin 5 (1)
- Clinical competence (1)
- Clinical genetics (1)
- Clinical skills (1)
- Clinical trial (1)
- Clinical trials (1)
- Clonidine (1)
- Clustering (1)
- Cofilin (1)
- Collagen antibody-induced arthritis (1)
- Comorbidities (1)
- Compartmental modeling (1)
- Complementary medicine (1)
- Complex I (1)
- Compliance (1)
- Complicated appendicitis (1)
- Computed tomography pulmonary angiography (CTPA) (1)
- Computer simulation (1)
- Conduct disorder (1)
- Congenital ocular motor apraxia (1)
- Conservation (1)
- Conventional Chemotherapeutic (1)
- Cord blood transplantation (1)
- Costs (1)
- Couch tracking (1)
- Craniomandibular disorders (1)
- Critical haematocrit (1)
- Croatia (1)
- Cross-border mobility (1)
- Cross-contamination (1)
- Cryo-electron microscopy (1)
- Cryoballoon (1)
- Curcumin micelles (1)
- Cytotoxic CD8+ T cell (1)
- D-wave (1)
- DKK1 (1)
- DNA damage (1)
- DNA methylation (1)
- DNA replication (1)
- DNA-protein crosslinks (1)
- Daptomycin (1)
- Databases (1)
- Decision making (1)
- Decision trees (1)
- Decision-making (1)
- Decolonization (1)
- Delivery mode (1)
- Delivery quality assurance (1)
- Dendritic spines (1)
- Denosumab (1)
- Density equalizing (1)
- Density equalizing mapping (1)
- Dentistry (1)
- Desinfektion von Flugzeugen (1)
- Desmin (1)
- Diagnosis (1)
- Digital breast tomosynthesis (DBT) (1)
- Digital mammography (1)
- Disinfection of aircraft (1)
- Distribution (1)
- Dogs (1)
- Domestic (1)
- Drug targeting (1)
- Drug therapy (1)
- Dual-Source CT (1)
- Dvc1 (1)
- E-learning (1)
- E. coli (1)
- E2F-1 (1)
- EGR1/2/3 (1)
- EQ (1)
- EQ-5D (1)
- ET (1)
- ET-MP (1)
- Early goal-directed therapy (1)
- Echocardiography (1)
- Eclampsia (1)
- Economic evaluation (1)
- Economic impact (1)
- Ecosystem health (1)
- Electron transport chain (1)
- Electrotonic analysis (1)
- Elimination (1)
- Emotion regulation (1)
- Emphysema (1)
- Employment effect (1)
- Emx2 (1)
- Endometriosis (1)
- Endoscopic ultrasound (1)
- Endothelial permeability (1)
- Entorhinal cortex lesion (1)
- Entwicklungsbiologie (1)
- EnvZ signalling (1)
- Envenomation (1)
- Epidermolysis bullosa simplex with muscular dystrophy (1)
- Epigenetik (1)
- Eradication (1)
- Erythema migrans (1)
- Erythrocytes (1)
- Erzähltheorie (1)
- Erzählung (1)
- Ethno-ophiology (1)
- Europe (1)
- Evaluation (1)
- Everolimus (1)
- Evidence-based medicine (1)
- Ewing sarcoma (1)
- Excitability (1)
- Exercise (1)
- Extracellular RNA (eRNA) (1)
- Eye movements (1)
- FF-ATP synthase dimer (1)
- FOLFIRI (1)
- Fc receptor (1)
- Feedback (1)
- Females (1)
- Fetal bovine serum (1)
- Fibrosis (1)
- First-line combination antiretroviral therapy (1)
- Fleas (1)
- Flexible Endoscopic Evaluation of Swallowing (1)
- Folic acid (1)
- Follow-up (1)
- Food and Drug Administration (1)
- Fortpflanzung (1)
- Frankincense (1)
- Functional capacity (1)
- Functional clustering (1)
- GSK2334470 (1)
- GVHD (1)
- Gallbladder percutaneous drainage (1)
- Gastritis (1)
- Gastrointestinal bleeding (1)
- Gastrointestinal neoplasm (1)
- Gender analysis (1)
- Gene (1)
- Gene expression (1)
- Gene ontology (1)
- General clinical cardiology (1)
- General practice/family medicine (1)
- Genetics research (1)
- Gestational diabetes (1)
- Gimbaled tracking (1)
- Gram-positive infection (1)
- Granule cell (1)
- Gross tumor volume optimization (1)
- Growth cone (1)
- Guideline (1)
- Guidelines (1)
- H3 receptor (1)
- HMA (1)
- HOXA profile (1)
- HOXB4 (1)
- Hawaii Department of Health (1)
- Health care workers (1)
- Health research (1)
- Health workforce governance (1)
- Heart regeneration (1)
- Hemodilution (1)
- Hemodynamic management (1)
- Hemostasis (1)
- Hepatitis C virus (1)
- Hepatitis c (1)
- Herd immunity (1)
- High-dose chemotherapy (1)
- Highly infectious diseases (1)
- Hochansteckende Krankheiten (1)
- Hodgkin lymphoma (1)
- Homeostasis (1)
- Homeostatic plasticity (1)
- Homocysteine (1)
- Honolulu Queen’s Medical Center (1)
- Hospital (1)
- Hospitals (1)
- Household contacts (1)
- Hrvaška (1)
- Human behaviour (1)
- Human physiology (1)
- Humans (1)
- Hypertext (1)
- I-wave (1)
- IAP proteins (1)
- IGRA (1)
- IKZF1 (1)
- IL-11 (1)
- IL-13 (1)
- IL-22 (1)
- IL-6 (1)
- IRX1 (1)
- Immobilization (1)
- Immune response (1)
- Immunity (1)
- Immunocompromised (1)
- Immunology and Microbiology Section (1)
- Immunosuppressive agents (1)
- Immunosuppressive therapy (1)
- In vitro (1)
- In vivo (1)
- Incidence (1)
- Individualized intervention (1)
- Indoor air pollution (1)
- Induced pluripotent stem cells (1)
- Infant (1)
- Inflow obstruction (1)
- Influenza (1)
- Intensive care (1)
- Intensive care unit (1)
- Interdisciplinarity (1)
- Intermediate filaments (1)
- Intratumoral (1)
- Invisible boundary paradigm (1)
- Iron deficiency anemia (1)
- Ischemia/reperfusion injury (1)
- Ischemia–reperfusion injury (1)
- Itpr1 (1)
- Jaw (1)
- Joint destruction (1)
- Joubert syndrome (1)
- Key stone species (1)
- Kidney transplantation (1)
- Kiefer (1)
- Kim-1 (1)
- Kinases (1)
- Kinematic posture analysis (1)
- Krait (1)
- Kraniomandibuläre Dysfunktion (1)
- Krankheit (1)
- LC3B (1)
- LDL-cholesterol (1)
- LOS (1)
- LTBI (1)
- Laparoscopic appendectomy (1)
- Learning outcomes (1)
- Lecithin (1)
- Lecture (1)
- Left ventricular assist device (1)
- Left ventricular non-compaction, (1)
- Lenalidomide (1)
- Length of stay (1)
- Lhx2 (1)
- Lice (1)
- Lineage tracing (1)
- Lipid metabolism (1)
- Lipid signaling (1)
- Lipid signalling (1)
- Liquid filled MicroLion ion chamber array (1)
- Liver cirrhosis (1)
- Liver metastases (1)
- Longitudinal (1)
- Low back pain (1)
- Ltbp4 (1)
- Lucigenin (1)
- Luftverkehr (1)
- Lyme borreliosis (1)
- Lyme disease (1)
- Lyme disease - Borreliosis (1)
- MEDIC (1)
- MEG (1)
- MLC tracking (1)
- MLL-Baby (1)
- MLL-rearranged leukemia (1)
- MMF (1)
- MPA (1)
- MPN (1)
- MPN-U (1)
- MR-based histology (1)
- MRI (1)
- MRP4 (1)
- MRSA (1)
- Machine-learning (1)
- Macrophage Transdifferentiation (1)
- Magnetic resonance (1)
- Major bleeding (1)
- Major infection after cardiac surgery (1)
- Manufacturing (1)
- Mapping (1)
- Measles (1)
- Medizinische Chemie (1)
- Meis1 (1)
- Meis2 (1)
- Meldepflicht (1)
- Membrane assays (1)
- Mental health (1)
- Mesenchymal stem/stromal cells (1)
- Metabolic diseases (1)
- Metagenomics (1)
- Metastatic breast cancer (1)
- Methicillin resistance (1)
- MicroRNAs (miRNAs) (1)
- Migrants (1)
- Minimal residual disease (1)
- Mitochondrial complex I (1)
- Modified FDI criteria (1)
- Molar tooth sign (1)
- Molecular biology (1)
- Molecular diagnosis (1)
- Molecular mechanisms of cancer (1)
- Monacolin K (1)
- Morphological modeling (1)
- Mortality (1)
- Motivational strategies (1)
- Motor control (1)
- Motor dysfunction (1)
- Multi-resistant pathogens (1)
- Multidetector Computed Tomography (1)
- Multimodal imaging (1)
- Multiple myeloma (1)
- Multiple sclerosis (1)
- Multivariate analysis (1)
- Muscarinic acetylcholine receptor (1)
- Muscle weakness (1)
- Muscular diseases (1)
- Musculoskeletal system (1)
- Muskuloskeletales System (1)
- Mutations (1)
- Myelopoiesis (1)
- NADH:ubiquinone oxidoreductase (1)
- NGS sequencing (1)
- NHE (1)
- NK cell (1)
- NK cell subset (1)
- NO (1)
- NS3 protease inhibitor (1)
- NSF (1)
- NXF1 (1)
- Nackenmuskulatur (1)
- Narrativ <Sozialwissenschaften> (1)
- Neck muscles (1)
- Neoplasms (1)
- Nerve regeneration (1)
- Nervous system diseases (1)
- Neurodegeneration (1)
- Neuroinflammation (1)
- Neurotoxicity (1)
- Nitric oxide (1)
- Non-RCT (1)
- Non-alcoholic fatty liver disease (1)
- Non-coding RNAs (1)
- Non-neuronal cholinergic system (1)
- Nonsteroidal anti-inflammatory drugs (1)
- Nox (1)
- Nox4 (1)
- Nrf2 (1)
- Nucleophosmin-1 (1)
- OECD performance standards (1)
- OPRM1 methylation (1)
- OSCE (1)
- Olfactory system (1)
- Oncolytic adenovirus (1)
- Open source concept (1)
- Opioid system (1)
- Oppositional defiant disorder (1)
- Organ motion (1)
- Osmosensing (1)
- Osteoporosis (1)
- Ovarian cancer (1)
- OxyELITE Pro (1)
- Oxygen consumption (1)
- PAD4 (1)
- PAR (1)
- PDK1 (1)
- PELICAN (1)
- PGE2 (1)
- PIF pocket (1)
- PMF (1)
- PV (1)
- Parainfluenza (1)
- Parkinson's disease (1)
- Particulate matter (1)
- Patellofemoral Joint (1)
- Path dependency (1)
- Pathogen reduction (1)
- Pdgfrβ (1)
- Peer-feedback (1)
- Peer-teaching (1)
- Pegylated liposomal doxorubicin (1)
- Persistence (1)
- Pharmacological treatment (1)
- Pharmacology (1)
- Phosphorylation (1)
- Physicians (1)
- Placental growth factor (1)
- Platelet (1)
- Platelet lysate (1)
- Platelet releasate (1)
- Plectin (1)
- Plk1 inhibitors (1)
- Policy implementation (1)
- Polo-like kinase 3 (1)
- Polyhexanide (1)
- Population-based screening (1)
- Porin regulation (1)
- Post-translational modifications (1)
- Pre-economic effects (1)
- Pre-emptive immunotherapy (1)
- Pre-treatment drug resistance mutations (1)
- Predictive medicine (1)
- Preeclampsia (1)
- Pregnancy (1)
- Primary care (1)
- Produkte zur Desinfektion (1)
- Protein aggregates (1)
- Protein interactions (1)
- Proximal humeral fracture (1)
- Pseudo HE-images (1)
- Pulse contour analysis (1)
- Pulse pressure variation (1)
- Quality of care (1)
- Quantitative MRI (1)
- RAG (1)
- RCT (1)
- RIPK3 (1)
- ROS generation (1)
- RT-qPCR (1)
- Radiofrequency (1)
- Raman spectroscopy (1)
- Randomised controlled trial (1)
- Randomized controlled trial (1)
- Rational use (1)
- Reactive oxygen species (1)
- Reading (1)
- Recall rate (1)
- Reconstructed human epidermis (1)
- Red blood cells (1)
- Red yeast rice (1)
- Redox (1)
- Regional health workforce monitoring (1)
- Regression analysis (1)
- Rehospitalization (1)
- Relapse (1)
- Relaxometry (1)
- Remote ischemic conditioning (1)
- Renal cell carcinoma (1)
- Renal function (1)
- Research architecture (1)
- Research impact assessment (1)
- Residential care (1)
- Resin composites (1)
- Respiration (1)
- Respiratory signs and symptoms (1)
- Respiratory syncytial virus (1)
- Rheumatoid arthritis (1)
- Rivaroxaban (1)
- Robotic tracking (1)
- Roma women (1)
- Rora (1)
- Ruijs-Aalfs syndrome (1)
- Ryanodine (1)
- S. cerevisiae (1)
- SAP (1)
- SCT (1)
- SPARTAN (1)
- SPRTN (1)
- SR protein (1)
- SRSF3 (1)
- SRSF7 (1)
- STAT3 (1)
- STIR (1)
- SW480 Cell (1)
- Salmonella infection (1)
- Schmerz (1)
- Science policy (1)
- Science structure (1)
- Scientometric analysis (1)
- Scientometrics (1)
- Sclerostin (1)
- Second stage of labor (1)
- Second-line treatment (1)
- Secondary mutations (1)
- Sensorimotor training (1)
- Sensory neuron (1)
- Sensory-motor training (1)
- Sepsis-bundle (1)
- Sequence (1)
- Sexualität (1)
- Signaling (1)
- Signaling ROS (1)
- Skeletal muscle (1)
- Skill mix (1)
- Skills training (1)
- Skin irritation test (1)
- Skin manifestation (1)
- Smac (1)
- Smooth muscle cell (1)
- Snake identification (1)
- Snake species diversity (1)
- Snake worship (1)
- Socioeconomic status (1)
- Software tool (1)
- Spectral library (1)
- Sphere Formation Assay (1)
- Standardized operating procedures (1)
- Standardverfahren (1)
- Stroke (1)
- Stroke Risk (1)
- Stroke prevention (1)
- Stroke volume variation (1)
- Strukturbasiertes Design (1)
- Substances for disinfection (1)
- Sulfhydryl-reactivity (1)
- Sulfur metabolism (1)
- Sunitinib (1)
- Superinfection (1)
- Superoxide (1)
- Surgery (1)
- Surgical risk (1)
- Surveillance (1)
- Sympathicolysis (1)
- Synaptic plasticity (1)
- Synaptopodin (1)
- Synovial inflammation (1)
- Systematic review (1)
- Systemic treatment (1)
- T cell/histiocyte rich large B cell lymphoma (1)
- T cells (1)
- T1 (1)
- T84 colon carcinoma cells (1)
- TAX1BP1 (1)
- TRAIL (1)
- Target identification (1)
- Targeted therapy (1)
- Tax effect (1)
- Tgfβ (1)
- Therapeutics (1)
- Thermodilution (1)
- Thermoplasma (1)
- Thiol redox modification (1)
- Thromboembolism (1)
- Thrombosis (1)
- Thrombosis/hypercoagulable states (1)
- Ticks (1)
- Topoisomerase (1)
- Transepithelial transport (1)
- Transfusion (1)
- Translational research (1)
- Translocation partner genes (1)
- Transmembrane communication (1)
- Transmission (1)
- Transsectoral governance (1)
- Trauma (1)
- Travellers (1)
- Treatment (1)
- Treatment protocol (1)
- Triterpenoids (1)
- Tumorsphere Formation (1)
- Tween 80 (1)
- Tyrosine kinase inhibitor (1)
- Tyrosine kinase inhibitor mTOR inhibition (1)
- Tyrosine kinases (1)
- USP9X (1)
- Uncomplicated appendicitis (1)
- Undergraduate training (1)
- Upper respiratory tract infection (1)
- Urban (1)
- VE-cadherin (1)
- Vaccination (1)
- Vaginal breech delivery (1)
- Vaginal delivery (1)
- Value-added effect (1)
- Vascular permeability (1)
- Viral load (1)
- Virological failure (1)
- Voltage attenuation (1)
- WRNIP1 (1)
- X-ray crystallography (1)
- XIAP (1)
- Yeast-2-Hybrid (1)
- Zoonosis (1)
- acetaminophen (1)
- acute coronary syndrome (1)
- acute leukemia (1)
- acute liver injury (1)
- acute lymphoblastic leukemia (1)
- acute myeloid leukemia (AML) (1)
- adalimumab (1)
- adenomatous polyposis (1)
- adenosine (1)
- adhesion (1)
- adipose tissue-derived stem cell (1)
- advance directive (1)
- advanced care planning (1)
- age-related macular degeneration (1)
- aging (1)
- allogeneic stem cell transplantation (1)
- allosteric regulation (1)
- alternative 3′ end processing (1)
- anal carcinoma (1)
- angiogenesis (1)
- angioplasty (1)
- angiopoietin-2 (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- animal host (1)
- animal models (1)
- antenatal characteristics (1)
- antenatalne značilnosti (1)
- anti-citrullinated protein antibodies (1)
- anticoagulants (1)
- anticonvulsant activity (1)
- antiviral (1)
- antiviral therapy (1)
- archaea (1)
- archaeosomes (1)
- artery (1)
- astrocytoma (1)
- asymmetric hearing (1)
- auditory development (1)
- autoantibodies (1)
- automatic environmental tobacco smoke emitter (1)
- behavior (1)
- binaural cochlear implants (1)
- bio-absorbable mesh (1)
- biochemistry (1)
- bioenergetics (1)
- biological mesh (1)
- biomarker (1)
- bone marrow metastasis (1)
- bone metastasis (1)
- brain metastases (1)
- brain states (1)
- brain stimulation (1)
- brainmass (1)
- brainsize (1)
- bromodomain (1)
- bromodomains (1)
- bronchial allergen challenge (1)
- burden of illness (1)
- c1orf124 (1)
- cPLA2 (1)
- cancer care (1)
- cancer care providers (1)
- cancer screening (1)
- candidate genes (1)
- carbapenem-resistant Gram-negative bacteria (CRGN) (1)
- carbapenemases (1)
- carboxyfluorescein (1)
- cardiovascular magnetic resonance (1)
- carotid (1)
- case study (1)
- catheterization/diagnostic interventional (1)
- cell biology (1)
- cell death (1)
- cell transplantation (1)
- cells (1)
- central nervous system infection (1)
- chemical probes (1)
- chemokines: CYP2D6 model (1)
- chemoradiotherapy (1)
- chromosome segregation (1)
- chronic hepatitis C (1)
- chronic viral hepatitis (1)
- cigarette smoke (1)
- citrullination (1)
- clinical psychology (1)
- clusteranalysis (1)
- cochlear implant (1)
- compartmental neuron model (1)
- complement (1)
- compliance (1)
- computational model (1)
- connectional fingerprint (1)
- connective tissue (1)
- continuing education (1)
- contralateral adaptations (1)
- cortical layers and areas (1)
- corticospinal (1)
- cross education (1)
- cross-modal plasticity (1)
- cryoEM (1)
- cryoelectron microscopy (1)
- cytokine (1)
- cytokines (1)
- cytotoxicity (1)
- deaf white cat (1)
- deafness (1)
- decision making (1)
- dedifferentiation (1)
- default network (1)
- dentate gyrus (1)
- dentist (1)
- depression (1)
- deprivation (1)
- desensitization (1)
- desmoplastic stroma (1)
- diclofenac (1)
- differentiation (1)
- diffuse large B cell lymphoma (1)
- diffusion MRI (1)
- diffusion tensor imaging (1)
- direct antiviral agents (1)
- drug resistance (1)
- eNOS (1)
- editorials (1)
- electrocardiography (1)
- electron cryomicroscopy (1)
- electron tomography (1)
- endothelial (1)
- endothelial cells (1)
- endothelial receptor expression (1)
- enhancer of transcription (1)
- environmental tobacco smoke (1)
- epigenetic (1)
- epilepsy (1)
- epithelial cells (1)
- epithelium (1)
- erosions (1)
- eutheria (1)
- exercise testing (1)
- exome sequencing (1)
- familial colorectal cancer (1)
- fasting (1)
- fear conditioning (1)
- fear generalization (1)
- fibrosarcoma (1)
- flurbiprofen (1)
- forkhead box protein o1 (1)
- fracture (1)
- gadobutrol (1)
- gastric cancer (1)
- gender (1)
- gene expression (1)
- gene expression profiling (1)
- gene expression profiling (GEP) (1)
- generic preparedness (1)
- genes (1)
- glucocorticoids (1)
- gold nanoparticles (1)
- governance (1)
- graph theory (1)
- green fluorescent protein (1)
- guideline (1)
- health-related quality of life (1)
- heartbeat-evoked responses (1)
- hepatitis c (1)
- hepatocytes (1)
- hepatotoxicity (1)
- herb induced liver injury (HILI) (1)
- herbal drug (1)
- herbal hepatotoxicity (1)
- hereditary angioedema (1)
- hereditary tumor syndromes (1)
- high-dose chemotherapy (1)
- histamine (1)
- histological validation (1)
- homoarginine (1)
- hormones (1)
- host response (1)
- human brain (1)
- human gingival fibroblasts (1)
- human natural killer cell (1)
- hypoxia (1)
- iCLIP (1)
- immune evasion (1)
- immune reconstitution (1)
- immunocompromised patient (1)
- immunologic (1)
- immunostaining (1)
- in situ hybridization (1)
- in situ vaccine (1)
- incisional hernia (1)
- infants (1)
- inflammation (1)
- influenza pandemic (1)
- information needs (1)
- innate immunity (1)
- inner membrane morphology (1)
- insertable cardiac monitor (1)
- interaural time difference (1)
- interferon (1)
- interferon-free antiviral treatment (1)
- interval training (1)
- invasion (1)
- irritable bowel syndrome (1)
- isomeric antagonists (1)
- kinase regulation (1)
- laser (1)
- laser based cell manipulation (1)
- laser microdissection (1)
- leukocytes (1)
- life span (1)
- liposomes (1)
- living will (1)
- local control (1)
- low-dose imaging (1)
- lymphoma pathogenesis (1)
- l‐arginine:glycine amidinotransferase (1)
- mRNA export (1)
- macrophages (1)
- magnetic resonance imaging (1)
- mammals (1)
- management (1)
- mandatory reporting system (1)
- mantle cell lymphoma (1)
- massive parallel sequencing (1)
- maturation (1)
- medical history (1)
- medication plan (1)
- medication schedule (1)
- medicinal chemistry (1)
- membrane protein complex (1)
- menthol (1)
- men’s (1)
- meta-analysis (1)
- metabolism (1)
- metalloprotease (1)
- miRNA (1)
- miRNA in immune cells (1)
- microbiome (1)
- microwave ablation (1)
- mirror training (1)
- mismatch repair (1)
- mitochondria (1)
- mitotic arrest (1)
- molecular dynamics (1)
- motor cortex (1)
- mouse (1)
- multi-drug resistance (1)
- multi-scale modeling (1)
- multidrug-resistant Gram-negative bacteria (MRGN) (1)
- multiresistente Gram-negativen Stäbchenbakterien (MRGN) (1)
- neuroblastoma (1)
- neuroinformatics (1)
- neuromodulation (1)
- nodular lymphocyte predominant Hodgkin lymphoma (1)
- noise intervention measures (1)
- nonnucleoside polymerase inhibitor (1)
- non‑Hodgkin's lymphoma (1)
- nuclear hormone receptor (1)
- nursery schools (1)
- observational study (1)
- occupational health (1)
- occupational stress (1)
- oncology (1)
- oral enzyme combination (1)
- orthodontist (1)
- osteoarthritis (1)
- osteoporosis (1)
- osteoporosis treatment (1)
- oval split ring resonator (1)
- overview (1)
- p21 phosphorylation (1)
- p21 stability (1)
- pandemic preparedness (1)
- patient safety (1)
- patient’s desires (1)
- pattern (1)
- perforin (1)
- perfusion (1)
- perinatal HIV infection (1)
- periodontal diseases (1)
- periodontitis (1)
- peripheral blood stem cell transplant (1)
- pharmacotherapy (1)
- phenotype (1)
- pirinixic acid (1)
- pirinixic acid derivative (1)
- pixantrone (1)
- pol g (1)
- pollen allergy (1)
- polo-like kinase (1)
- polycystic kidney (1)
- post hoc study (1)
- prefrontal cortex (1)
- prevention (1)
- primary motor cortex (1)
- progenitor (1)
- progeria (1)
- prognosis (1)
- proliferation (1)
- prophylaxis (1)
- protein kinase (1)
- proto-oncogene proteins c-akt (1)
- proximal tubule (1)
- psoriatic arthritis (1)
- psychopathology (1)
- psychotherapy (1)
- public health. (1)
- radiological (1)
- randomized controlled trial (1)
- rat model (1)
- real-world data (1)
- relapse (1)
- renal impairment (1)
- retuximab (1)
- risk communication (1)
- rituximab (1)
- rna (1)
- romske ženske (1)
- rotary ATPase mechanism (1)
- salvage therapy (1)
- schizophrenia (1)
- scientometrics (1)
- self (1)
- senescence (1)
- sensory deprivation (1)
- sex‑determining region Y-box 11 (1)
- signal transduction (1)
- signature (1)
- single particle (1)
- single‐photon emission (1)
- size of cigarettes (1)
- skin conductance (1)
- skin involvement (1)
- sleep (1)
- slow-wave rhythms (1)
- smac mimetic (1)
- small compounds (1)
- sound analyses (1)
- sphingolipid (1)
- spirochetes (1)
- spontaneous cognition (1)
- stellate reticulum (1)
- stereoselectivity (1)
- stress (1)
- stress response (1)
- stroke prevention (1)
- structure-based design (1)
- sulforaphane (1)
- survey (1)
- systematic review (1)
- targeted therapy (1)
- teratoma (1)
- testosterone (1)
- tetraether lipid (1)
- theranostics (1)
- therapy at the end of life (1)
- tobacco taxation (1)
- tolerance (1)
- tp63 gene (1)
- training (1)
- transcranial magnetic stimulation (1)
- transcription factor (1)
- treatment (1)
- treatment outcome (1)
- trophiclevel (1)
- tumor immune escape (1)
- ubiquitin (1)
- ubiquitin coat (1)
- ubiquitin-binding zinc finger (1)
- ultra-high field MRI (1)
- vascular endothelial growth factor (1)
- vertebrates (1)
- vessel density (1)
- virological failure (1)
- waking state (1)
- western blotting (1)
- work ability (1)
- working conditions (1)
- xenobiotics (1)
- xenophagy (1)
- yeast (1)
- young people (1)
- μ-opioid receptor regulation (1)
- дети первого года жизни (1)
- исходы терапии (1)
- острые лейкозы (1)
- перестройки 11q23/MLL (1)
Institute
- Medizin (285)
- Pharmazie (18)
- Biowissenschaften (12)
- Biochemie und Chemie (11)
- MPI für Hirnforschung (7)
- Exzellenzcluster Makromolekulare Komplexe (6)
- Georg-Speyer-Haus (6)
- Präsidium (6)
- Frankfurt Institute for Advanced Studies (FIAS) (5)
- Psychologie (5)
1. Objective: Chronic hepatitis C virus infections (HCV) cause a significant public health burden. Introduction of telaprevir (TVR) and boceprevir (BOC) has increased sustained virologic response rates (SVR) in genotype 1 patients but were accompanied by higher treatment costs and more side effects. Aim of the study was to assess outcomes and costs of treating HCV with TVR or BOC in routine care.
2. Material and Methods: Data was obtained from a non-interventional study. This analysis relates on a subset of 1,786 patients for whom resource utilisation was documented. Sociodemografic and clinical parameters as well as resource utilisation were collected using a web-based data recording system. Costs were calculated using official remuneration schemes.
3. Results: Mean age of patients was 49.2 years, 58.6% were male. In treatment-naive patients SVR-rates of 62.2% and 55.7% for TVR and BOC were observed (prior relapser: 68.5% for TVR and 63.5% for BOC; prior nonresponder: 45.6% for TVR and 39.1% for BOC). Treatment costs are dominated by costs for pharmaceuticals and range between €39,081 and €53,491. We calculated average costs per SVR of €81,347 (TVR) and €70,163 (BOC) in treatment-naive patients (prior relapser: 78,089 €/SVR for TVR and 82,077 €/SVR for BOC; prior non-responder: 116,509 €/SVR for TVR and 110,156 €/SVR for BOC). Quality of life data showed a considerable decrease during treatment.
4. Conclusion: Our study is one of few investigating both, outcomes and costs, of treating HCV in a real-life setting. Data can serve as a reference in the discussion of increasing costs in recently introduced agents
Mitochondrial cristae are connected to the inner boundary membrane via crista junctions which are implicated in the regulation of oxidative phosphorylation, apoptosis, and import of lipids and proteins. The MICOS complex determines formation of crista junctions. We performed complexome profiling and identified Mic13, also termed Qil1, as a subunit of the MICOS complex. We show that MIC13 is an inner membrane protein physically interacting with MIC60, a central subunit of the MICOS complex. Using the CRISPR/Cas method we generated the first cell line deleted for MIC13. These knockout cells show a complete loss of crista junctions demonstrating that MIC13 is strictly required for the formation of crista junctions. MIC13 is required for the assembly of MIC10, MIC26, and MIC27 into the MICOS complex. However, it is not needed for the formation of the MIC60/MIC19/MIC25 subcomplex suggesting that the latter is not sufficient for crista junction formation. MIC13 is also dispensable for assembly of respiratory chain complexes and for maintaining mitochondrial network morphology. Still, lack of MIC13 resulted in a moderate reduction of mitochondrial respiration. In summary, we show that MIC13 has a fundamental role in crista junction formation and that assembly of respiratory chain supercomplexes is independent of mitochondrial cristae shape.
Background & Aim: The resistance profile of anti-hepatitis C virus (HCV) agents used in combination is important to guide optimal treatment regimens. We evaluated baseline and treatment-emergent NS3/4A and NS5B amino-acid variants among HCV genotype (GT)-1a and -1b-infected patients treated with faldaprevir (HCV protease inhibitor), deleobuvir (HCV polymerase non-nucleoside inhibitor), and ribavirin in multiple clinical studies.
Methods: HCV NS3/4A and NS5B population sequencing (Sanger method) was performed on all baseline plasma samples (n = 1425 NS3; n = 1556 NS5B) and on post-baseline plasma samples from patients with virologic failure (n = 113 GT-1a; n = 221 GT-1b). Persistence and time to loss of resistance-associated variants (RAVs) was estimated using Kaplan–Meier analysis.
Results: Faldaprevir RAVs (NS3 R155 and D168) and deleobuvir RAVs (NS5B 495 and 496) were rare (<1%) at baseline. Virologic response to faldaprevir/deleobuvir/ribavirin was not compromised by common baseline NS3 polymorphisms (e.g. Q80K in 17.5% of GT-1a) or by NS5B A421V, present in 20% of GT-1a. In GT-1b, alanine at NS5B codon 499 (present in 15% of baseline sequences) was associated with reduced response. Treatment-emergent RAVs consolidated previous findings: NS3 R155 and D168 were key faldaprevir RAVs; NS5B A421 and P495 were key deleobuvir RAVs. Among on-treatment virologic breakthroughs, RAVs emerged in both NS3 and NS5B (>90%). Virologic relapse was associated with RAVs in both NS3 and NS5B (53% GT-1b; 52% GT-1b); some virologic relapses had NS3 RAVs only (47% GT-1a; 17% GT-1b). Median time to loss of GT-1b NS5B P495 RAVs post-treatment (5 months) was less than that of GT-1b NS3 D168 (8.5 months) and GT-1a R155 RAVs (11.5 months).
Conclusion: Faldaprevir and deleobuvir RAVs are more prevalent among virologic failures than at baseline. Treatment response was not compromised by common NS3 polymorphisms; however, alanine at NS5B amino acid 499 at baseline (wild-type in GT-1a, polymorphism in GT-1b) may reduce response to this deleobuvir-based regimen.
Introduction: Sepsis remains associated with a high mortality rate. Endotoxin has been shown to influence viscoelastic coagulation parameters, thus suggesting a link between endotoxin levels and the altered coagulation phenotype in septic patients. This study evaluated the effects of systemic polyspecific IgM-enriched immunoglobulin (IgM-IVIg) (Pentaglobin® [Biotest, Dreieich, Germany]) on endotoxin activity (EA), inflammatory markers, viscoelastic and conventional coagulation parameters.
Methods: Patients with severe sepsis were identified by daily screening in a tertiary, academic, surgical ICU. After the inclusion of 15 patients, the application of IgM-IVIg (5 mg/kg/d over three days) was integrated into the unit’s standard operation procedure (SOP) to treat patients with severe sepsis, thereby generating “control” and “IgM-IVIg” groups. EA assays, thrombelastometry (ROTEM®) and impedance aggregometry (Multiplate®) were performed on whole blood. Furthermore, routine laboratory parameters were determined according to unit’s standards.
Results: Data from 26 patients were included. On day 1, EA was significantly decreased in the IgM-IVIg group following 6 and 12 hours of treatment (0.51 ±0.06 vs. 0.26 ±0.07, p<0.05 and 0.51 ±0.06 vs. 0.25 ±0.04, p<0.05) and differed significantly compared with the control group following 6 hours of treatment (0.26 ±0.07 vs. 0.43 ±0.07, p<0.05). The platelet count was significantly higher in the IgM-IVIg group following four days of IgM-IVIg treatment (200/nl ±43 vs. 87/nl ±20, p<0.05). The fibrinogen concentration was significantly lower in the control group on day 2 (311 mg/dl ±37 vs. 475 mg/dl ±47 (p = 0.015)) and day 4 (307 mg/dl ±35 vs. 420 mg/dl ±16 (p = 0.017)). No differences in thrombelastometric or aggregometric measurements, or inflammatory markers (interleukin-6 (IL-6), leukocyte, lipopolysaccharide binding protein (LBP)) were observed.
Conclusion: Treatment with IgM-enriched immunoglobulin attenuates the EA levels in patients with severe sepsis and might have an effect on septic thrombocytopenia and fibrinogen depletion. Viscoelastic, aggregometric or inflammatory parameters were not influenced.
Abstract: Integration of synaptic currents across an extensive dendritic tree is a prerequisite for computation in the brain. Dendritic tapering away from the soma has been suggested to both equalise contributions from synapses at different locations and maximise the current transfer to the soma. To find out how this is achieved precisely, an analytical solution for the current transfer in dendrites with arbitrary taper is required. We derive here an asymptotic approximation that accurately matches results from numerical simulations. From this we then determine the diameter profile that maximises the current transfer to the soma. We find a simple quadratic form that matches diameters obtained experimentally, indicating a fundamental architectural principle of the brain that links dendritic diameters to signal transmission.
Author Summary: Neurons take a great variety of shapes that allow them to perform their different computational roles across the brain. The most distinctive visible feature of many neurons is the extensively branched network of cable-like projections that make up their dendritic tree. A neuron receives current-inducing synaptic contacts from other cells across its dendritic tree. As in the case of botanical trees, dendritic trees are strongly tapered towards their tips. This tapering has previously been shown to offer a number of advantages over a constant width, both in terms of reduced energy requirements and the robust integration of inputs at different locations. However, in order to predict the computations that neurons perform, analytical solutions for the flow of input currents tend to assume constant dendritic diameters. Here we introduce an asymptotic approximation that accurately models the current transfer in dendritic trees with arbitrary, continuously changing, diameters. When we then determine the diameter profiles that maximise current transfer towards the cell body we find diameters similar to those observed in real neurons. We conclude that the tapering in dendritic trees to optimise signal transmission is a fundamental architectural principle of the brain.
Optimizing spike-sorting algorithms is difficult because sorted clusters can rarely be checked against independently obtained “ground truth” data. In most spike-sorting algorithms in use today, the optimality of a clustering solution is assessed relative to some assumption on the distribution of the spike shapes associated with a particular single unit (e.g., Gaussianity) and by visual inspection of the clustering solution followed by manual validation. When the spatiotemporal waveforms of spikes from different cells overlap, the decision as to whether two spikes should be assigned to the same source can be quite subjective, if it is not based on reliable quantitative measures. We propose a new approach, whereby spike clusters are identified from the most consensual partition across an ensemble of clustering solutions. Using the variability of the clustering solutions across successive iterations of the same clustering algorithm (template matching based on K-means clusters), we estimate the probability of spikes being clustered together and identify groups of spikes that are not statistically distinguishable from one another. Thus, we identify spikes that are most likely to be clustered together and therefore correspond to consistent spike clusters. This method has the potential advantage that it does not rely on any model of the spike shapes. It also provides estimates of the proportion of misclassified spikes for each of the identified clusters. We tested our algorithm on several datasets for which there exists a ground truth (simultaneous intracellular data), and show that it performs close to the optimum reached by a support vector machine trained on the ground truth. We also show that the estimated rate of misclassification matches the proportion of misclassified spikes measured from the ground truth data.
Purpose: Quantitative T2'-mapping detects regional changes of the relation of oxygenated and deoxygenated hemoglobin (Hb) by using their different magnetic properties in gradient echo imaging and might therefore be a surrogate marker of increased oxygen extraction fraction (OEF) in cerebral hypoperfusion. Since elevations of cerebral blood volume (CBV) with consecutive accumulation of Hb might also increase the fraction of deoxygenated Hb and, through this, decrease the T2’-values in these patients we evaluated the relationship between T2’-values and CBV in patients with unilateral high-grade large-artery stenosis.
Materials and Methods Data from 16 patients (13 male, 3 female; mean age 53 years) with unilateral symptomatic or asymptomatic high-grade internal carotid artery (ICA) or middle cerebral artery (MCA) stenosis/occlusion were analyzed. MRI included perfusion-weighted imaging and high-resolution T2’-mapping. Representative relative (r)CBV-values were analyzed in areas of decreased T2’ with different degrees of perfusion delay and compared to corresponding contralateral areas.
Results: No significant elevations in cerebral rCBV were detected within areas with significantly decreased T2’-values. In contrast, rCBV was significantly decreased (p<0.05) in regions with severe perfusion delay and decreased T2’. Furthermore, no significant correlation between T2’- and rCBV-values was found. Conclusions rCBV is not significantly increased in areas of decreased T2’ and in areas of restricted perfusion in patients with unilateral high-grade stenosis. Therefore, T2’ should only be influenced by changes of oxygen metabolism, regarding our patient collective especially by an increase of the OEF. T2’-mapping is suitable to detect altered oxygen consumption in chronic cerebrovascular disease.
Responses to recent infectious disease outbreaks, such as to Influenza Pandemic 2009 and the on-going Ebola outbreak in West Africa, reveal the need for new and strengthened approaches to risk communication and governance. The article argues for a fundamental re-conceptualisation of current approaches to risk communication, preparedness planning and response. It calls for a reframing of the way we currently identify and respond to outbreaks around a set of core behaviour-based response patterns. This new model moves away from the current risk communication focus on a plethora of agent-specific threats to five generic response patterns that are based on socially relevant response activities such as 1) controlling vectors, 2) enhancing hygiene, 3) isolation of the sick, 4) protection of the well, and 5) systemic protection of people and their environments. Emphasis is placed on gaining relevant insights into the context specific needs of different communities related to these five patterns. Governance structures are then built and evaluated based on their capacity to collect, communicate, share and prepare the public to take appropriate action related to the five different patterns before, during and after an event. Reframing risk communication and preparedness approaches around a better understanding of the determinants of these general behavioural patterns in infectious control could strengthen infection control literacy, response competence and build resilience of both individuals and health systems to address future epidemics, pandemics and other public health threats.
Nuclear export factor 1 (NXF1) exports mRNA to the cytoplasm after recruitment to mRNA by specific adaptor proteins. How and why cells use numerous different export adaptors is poorly understood. Here we critically evaluate members of the SR protein family (SRSF1-7) for their potential to act as NXF1 adaptors that couple pre-mRNA processing to mRNA export. Consistent with this proposal, >1000 endogenous mRNAs required individual SR proteins for nuclear export in vivo. To address the mechanism, transcriptome-wide RNA-binding profiles of NXF1 and SRSF1-7 were determined in parallel by individual-nucleotide-resolution UV cross-linking and immunoprecipitation (iCLIP). Quantitative comparisons of RNA-binding sites showed that NXF1 and SR proteins bind mRNA targets at adjacent sites, indicative of cobinding. SRSF3 emerged as the most potent NXF1 adaptor, conferring sequence specificity to RNA binding by NXF1 in last exons. Interestingly, SRSF3 and SRSF7 were shown to bind different sites in last exons and regulate 3' untranslated region length in an opposing manner. Both SRSF3 and SRSF7 promoted NXF1 recruitment to mRNA. Thus, SRSF3 and SRSF7 couple alternative splicing and polyadenylation to NXF1-mediated mRNA export, thereby controlling the cytoplasmic abundance of transcripts with alternative 3' ends.
Background: Water-filtered infrared-A (wIRA) is a special form of heat radiation with high tissue penetration and a low thermal load to the skin surface. wIRA corresponds to the major part of the sun’s heat radiation, which reaches the surface of the Earth in moderate climatic zones filtered by water and water vapour of the atmosphere. wIRA promotes healing of acute and chronic wounds both by thermal and thermic as well as by non-thermal and non-thermic cellular effects.
Methods: This publication includes a literature review with search in PubMed/Medline for “water-filtered infrared-A” and “wound”/”ulcus” or “wassergefiltertes Infrarot A” and “Wunde”/”Ulkus”, respectively (publications in English and German), and additional analysis of study data. Seven prospective clinical studies (of these six randomized controlled trials (RCT), the largest study with n=400 patients) were identified and included. All randomized controlled clinical trials compare a combination of high standard care plus wIRA treatment vs. high standard care alone. The results below marked with “vs.” present these comparisons.
Results:
* wIRA increases tissue temperature (+2.7°C at a tissue depth of 2 cm), tissue oxygen partial pressure (+32% at a tissue depth of 2 cm) and tissue perfusion (effect sizes within the wIRA group).
* wIRA promotes normal as well as disturbed wound healing by diminishing inflammation and exudation, by promotion of infection defense and regeneration, and by alleviation of pain (with respect to alleviation of pain, without any exception during 230 irradiations, 13.4 vs. 0.0 on a visual analogue scale (VAS 0–100), median difference between groups 13.8, 95% confidence interval (CI) 12.3/16.7, p<0.000001) with a substantially reduced need for analgesics (52–69% less in the three groups with wIRA compared to the three control groups in visceral surgery, p=0.000020 and 0.00037 and 0.0045, respectively; total of 6 vs. 14.5 analgesic tablets on 6 surveyed days (of weeks 1–6) in chronic venous stasis ulcers, median difference –8, 95% CI –10/–5, p=0.000002).
Further effects are:
* Faster reduction of wound area (in severely burned children: 90% reduction of wound size after 9 vs. 13 days, after 9 days 89.2% vs. 49.5% reduction in wound area, median difference 39.5% wound area reduction, 95% CI 36.7%/42.2%, p=0.000011; complete wound closure of chronic venous stasis ulcers after 14 vs. 42 days, median difference –21 days, 95% CI –28/–10, p=0.000005).
* Better overall evaluation of wound healing (surgical wounds: 88.6 vs. 78.5 on a VAS 0–100, median difference 8.9, 95% CI 6.1/12.0, p<0.000001).
* Better overall evaluation of the effect of irradiation (79.0 vs. 46.8 on a VAS 0–100 with 50 as neutral point, median difference 27.9, 95% CI 19.8/34.6, p<0.000001).
* Higher tissue oxygen partial pressure during irradiation with wIRA (at a tissue depth of 2 cm 41.6 vs. 30.2 mmHg, median difference 11.9 mmHg, 95% CI 9.6/14.2 mmHg, p<0.000001).
* Higher tissue temperature during irradiation with wIRA (at a tissue depth of 2 cm 38.9 vs. 36.4°C, median difference 2.6°C, 95% CI 2.2/2.9°C, p<0.000001).
* Better cosmetic result (84.5 vs. 76.5 on a VAS 0–100, median difference 7.9, 95% CI 3.7/12.0, p=0.00027).
* Lower wound infection rate (single preoperative irradiation: 5.1% vs. 12.1% wound infections in total, difference –7.0%, 95% CI –12.8%/–1.3%, p=0.017, of these: late wound infections (postoperative days 9-30) 1.7% vs. 7.7%, difference –6.0%, 95% CI –10.3%/–1.7%, p=0.007).
* Shorter hospital stay (9 vs. 11 postoperative days, median difference –2 days, 95% CI –3/0 days, p=0.022).
Most of the effects have been proven with an evidence level of 1a or 1b.
Conclusion: Water-filtered infrared-A is a useful complement for the treatment of acute and chronic wounds.
Keywords: water-filtered infrared-A (wIRA), wound healing, acute and chronic wounds, reduction of pain, tissue oxygen partial pressure, tissue temperature
As current classical Hodgkin lymphoma (cHL) treatment strategies have pronounced side-effects, specific inhibition of signaling pathways may offer novel strategies in cHL therapy. Basal autophagy, a regulated catabolic pathway to degrade cell's own components, is in cancer linked with both, tumor suppression or promotion. The finding that basal autophagy enhances tumor cell survival would thus lead to immediately testable strategies for novel therapies. Thus, we studied its contribution in cHL.We found constitutive activation of autophagy in cHL cell lines and primary tissue. The expression of key autophagy-relevant proteins (e.g. Beclin-1, ULK1) and LC3 processing was increased in cHL cells, even in lymphoma cases. Consistently, cHL cells exhibited elevated numbers of autophagic vacuoles and intact autophagic flux. Autophagy inhibition with chloroquine or inactivation of ATG5 induced apoptosis and reduced proliferation of cHL cells. Chloroquine-mediated inhibition of basal autophagy significantly impaired HL growth in-vivo in NOD SCID γc-/- (NSG) mice. We found that basal autophagy plays a pivotal role in sustaining mitochondrial function.We conclude that cHL cells require basal autophagy for growth, survival and sustained metabolism making them sensitive to autophagy inhibition. This suggests basal autophagy as useful target for new strategies in cHL treatment.
The aim of this preliminary prospective RCT was to histologically evaluate peri-implant soft tissues around titanium abutments treated using different cleaning methods. Sixteen patients were randomized into three groups: laboratory customized abutments underwent Plasma of Argon treatment (Plasma Group), laboratory customized abutments underwent cleaning by steam (Steam Group), and abutments were used as they came from industry (Control Group). Seven days after the second surgery, soft tissues around abutments were harvested. Samples were histologically analyzed. Soft tissues surrounding Plasma Group abutments predominantly showed diffuse chronic infiltrate, almost no acute infiltrate, with presence of few polymorphonuclear neutrophil granulocytes, and a diffuse presence of collagenization bands. Similarly, in Steam Group, the histological analysis showed a high variability of inflammatory expression factors. Tissues harvested from Control Group showed presence of few neutrophil granulocytes, moderate presence of lymphocytes, and diffuse collagenization bands in some sections, while they showed absence of acute infiltrate in 40% of sections. However, no statistical difference was found among the tested groups for each parameter (p > 0.05). Within the limit of the present study, results showed no statistically significant difference concerning inflammation and healing tendency between test and control groups.
Objectives: Patient safety is a crucial issue in medicine. Its main objective is to reduce the number of deaths and health damages that are caused by preventable medical errors. To achieve this, it needs better health systems that make mistakes less likely and their effects less detrimental without blaming health workers for failures. Until now, there is no in-depth scientometric analysis on this issue that encompasses the interval between 1963 and 2014. Therefore, the aim of this study is to sketch a landscape of the past global research output on patient safety including the gender distribution of the medical discipline of patient safety by interpreting scientometric parameters. Additionally, respective future trends are to be outlined.
Setting: The Core Collection of the scientific database Web of Science was searched for publications with the search term ‘Patient Safety’ as title word that was focused on the corresponding medical discipline. The resulting data set was analysed by using the methodology implemented by the platform NewQIS. To visualise the geographical landscape, state-of-the-art techniques including density-equalising map projections were applied.
Results: 4079 articles on patient safety were identified in the period from 1900 to 2014. Most articles were published in North America, the UK and Australia. In regard to the overall number of publications, the USA is the leading country, while the output ratio to the population of Switzerland was found to exhibit the best performance. With regard to the ratio of the number of publications to the Gross Domestic Product (GDP) per Capita, the USA remains the leading nation but countries like India and China with a low GDP and high population numbers are also profiting.
Conclusions: Though the topic is a global matter, the scientific output on patient safety is centred mainly in industrialised countries.
A hallmark of several major neurological diseases is neuronal cell death. In addition to this primary pathology, secondary injury is seen in connected brain regions in which neurons not directly affected by the disease are denervated. These transneuronal effects on the network contribute considerably to the clinical symptoms. Since denervated neurons are viable, they are attractive targets for intervention. Therefore, we studied the role of Sphingosine-1-phosphate (S1P)-receptor signaling, the target of Fingolimod (FTY720), in denervation-induced dendritic atrophy. The entorhinal denervation in vitro model was used to assess dendritic changes of denervated mouse dentate granule cells. Live-cell microscopy of GFP-expressing granule cells in organotypic entorhino-hippocampal slice cultures was employed to follow individual dendritic segments for up to 6 weeks after deafferentation. A set of slice cultures was treated with FTY720 or the S1P-receptor (S1PR) antagonist VPC23019. Lesion-induced changes in S1P (mass spectrometry) and S1PR-mRNA levels (laser microdissection and qPCR) were determined. Denervation caused profound changes in dendritic stability. Dendritic elongation and retraction events were markedly increased, resulting in a net reduction of total dendritic length (TDL) during the first 2 weeks after denervation, followed by a gradual recovery in TDL. These changes were accompanied by an increase in S1P and S1PR1- and S1PR3-mRNA levels, and were not observed in slice cultures treated with FTY720 or VPC23019. We conclude that inhibition of S1PR signaling prevents dendritic destabilization and denervation-induced dendrite loss. These results suggest a novel neuroprotective effect for pharmaceuticals targeting neural S1PR pathways.
A 79 year old female patient was admitted to our emergency department with a fracture of the right medial femoral neck six days after a fall on her right side and a cemented hemiprosthesis was implanted. Five days later, she developed a hemorrhagic shock and was diagnosed with a delayed splenic rupture and the spleen was resected. Histopathological examination showed a delayed rupture of an otherwise normal spleen without signs of an underlying pathology. The outcome was fatal: In the postoperative course she developed pneumonia, three weeks later she succumbed due to multiple organ failure.
Even careful reevaluation of the case did not provide any clues to expect an injury of the spleen according to trauma mechanism.
This case shows that delayed splenic rupture of a normal spleen may occur even after a low energy trauma. Injury of the spleen should therefore always be considered, even with an uncharacteristic anamnesis. Physical examination after trauma should therefore always include a careful clinical evaluation. The clinical threshold for a FAST examination should be low.
The coincidence of a femoral neck fracture and a splenic rupture after a low energy trauma has not been reported before.
Background The endogenous amino acid homoarginine predicts mortality in cerebro‐ and cardiovascular disease. The objective was to explore whether homoarginine is associated with atrial fibrillation (AF) and outcome in patients with acute chest pain.
Methods and Results One thousand six hundred forty‐nine patients with acute chest pain were consecutively enrolled in this study, of whom 589 were diagnosed acute coronary syndrome (ACS). On admission, plasma concentrations of homoarginine as well as brain natriuretic peptide (BNP), and high‐sensitivity assayed troponin I (hsTnI) were determined along with electrocardiography (ECG) variables. During a median follow‐up of 183 days, 60 major adverse cardiovascular events (MACEs; 3.8%), including all‐cause death, myocardial infarction, or stroke, were registered in the overall study population and 43 MACEs (7.5%) in the ACS subgroup. Adjusted multivariable Cox regression analyses revealed that an increase of 1 SD of plasma log‐transformed homoarginine (0.37) was associated with a hazard reduction of 26% (hazard ratio [HR], 0.74; 95% CI, 0.57–0.96) for incident MACE and likewise of 35% (HR, 0.65; 95% CI, 0.49–0.88) in ACS patients. In Kaplan–Meier survival curves, homoarginine was predictive for patients with high‐sensitivity assayed troponin I (hsTnI) above 27 ng/L (P<0.05). Last, homoarginine was inversely associated with QTc duration (P<0.001) and prevalent AF (OR, 0.83; 95% CI, 0.71–0.95).
Conclusion Low plasma homoarginine was identified as a risk marker for incident MACEs in patients with acute chest pain, in particular, in those with elevated hsTnI. Impaired homoarginine was associated with prevalent AF. Further studies are needed to investigate the link to AF and evaluate homoarginine as a therapeutic option for these patients.
BACKGROUND: We retrospectively evaluated the efficacy and toxicity of gross tumor volume (GTV) mean-dose-optimized and real-time motion-compensated robotic stereotactic body radiation therapy (SBRT) in the treatment of liver metastases.
METHODS: Between March 2011 and July 2015, 52 patients were treated with SBRT for a total of 91 liver metastases (one to four metastases per patient) with a median GTV volume of 12 cc (min 1 cc, max 372 cc). The optimization of mean GTV dose was prioritized during treatment planning at the potential cost of planning target volume (PTV) coverage reduction while adhering to safe normal tissue constraints. The delivered median GTV biological effective dose (BED10) was 142.1 Gy10 (range, 60.2 Gy10 -165.3 Gy10) and the prescribed PTV BED10 ranged from 40.6 Gy10 to 112.5 Gy10 (median, 86.1 Gy10). We analyzed local control (LC), progression-free interval (PFI), overall survival (OS), and toxicity.
RESULTS: Median follow-up was 17 months (range, 2-49 months). The 2-year actuarial LC, PFI, and OS rates were 82.1, 17.7, and 45.0 %, and the median PFI and OS were 9 and 23 months, respectively. In univariate analysis histology (p < 0.001), PTV prescription BED10 (HR 0.95, CI 0.91-0.98, p = 0.002) and GTV mean BED10 (HR 0.975, CI 0.954-0.996, p = 0.011) were predictive for LC. Multivariate analysis showed that only extrahepatic disease status at time of treatment was a significant factor (p = 0.033 and p = 0.009, respectively) for PFI and OS. Acute nausea or fatigue grade 1 was observed in 24.1 % of the patients and only 1 patient (1.9 %) had a side effect of grade ≥ 2.
CONCLUSIONS: Robotic real-time motion-compensated SBRT is a safe and effective treatment for one to four liver metastases. Reducing the PTV prescription dose and keeping a high mean GTV dose allowed the reduction of toxicity while maintaining a high local control probability for the treated lesions.
Cortical development extensively depends on sensory experience. Effects of congenital monaural and binaural deafness on cortical aural dominance and representation of binaural cues were investigated in the present study. We used an animal model that precisely mimics the clinical scenario of unilateral cochlear implantation in an individual with single-sided congenital deafness. Multiunit responses in cortical field A1 to cochlear implant stimulation were studied in normal-hearing cats, bilaterally congenitally deaf cats (CDCs), and unilaterally deaf cats (uCDCs). Binaural deafness reduced cortical responsiveness and decreased response thresholds and dynamic range. In contrast to CDCs, in uCDCs, cortical responsiveness was not reduced, but hemispheric-specific reorganization of aural dominance and binaural interactions were observed. Deafness led to a substantial drop in binaural facilitation in CDCs and uCDCs, demonstrating the inevitable role of experience for a binaural benefit. Sensitivity to interaural time differences was more reduced in uCDCs than in CDCs, particularly at the hemisphere ipsilateral to the hearing ear. Compared with binaural deafness, unilateral hearing prevented nonspecific reduction in cortical responsiveness, but extensively reorganized aural dominance and binaural responses. The deaf ear remained coupled with the cortex in uCDCs, demonstrating a significant difference to deprivation amblyopia in the visual system.
The wide range of immunosuppressive therapies and protocols permits tailored planning of the initial regimen according to the immunological risk status of individual patients. Pre-transplant risk assessment can include many factors, but there is no clear consensus on which parameters to take into account, and their relative importance. In general younger patients are known to be at higher risk for acute rejection, compounded by higher rates of non-adherence in adolescents. Donor age and recipient gender do not appear to exert a meaningful effect on risk of rejection per se, but black recipient ethnicity remains a well-established risk factor even under modern immunosuppression regimens. Little difference in risk is now observed between deceased- and living-donor recipients. Immunological risk assessment has developed substantially in recent years. Cross-match testing with cytotoxic analysis has long been supplemented by flow cytometry, but development of solid-phase single-bead antigen testing of solubilized human leukocyte antigens (HLA) to detect donor-specific antibodies (DSA) permits a far more nuanced stratification of immunological risk status, including the different classes and intensities of HLA antibodies Class I and/or II, including HLA-DSA. Immunologic risk evaluation is now often based on a combination of these tests, but other assessments are becoming more widely introduced, such as measurement of non-HLA antibodies against angiotensin type 1 (AT1) receptors or T-cell ELISPOT assay of alloantigen-specific donor. Targeted densensitization protocols can improve immunological risk, notably for DSA-positive patients with negative cytotoxicity and flow cross-match. HLA mismatch remains an important and undisputed risk factor for rejection. Delayed graft function also increases the risk of subsequent acute rejection, and the early regimen can be modified in such cases. Overall, there is a shift towards planning the immunosuppressive regimen based on pre-transplant immunology testing although certain conventional risk factors retain their importance.
Background: It is occasionally difficult to distinguish the stellate reticulum-like region of ameloblastoma from the fibrous connective tissue stroma. This difficulty is further pronounced in the plexiform variant of ameloblastoma that has very sparse fibrous connective tissue.
Aim: To test the utility of Azan trichrome stain in marking tumour regions and the peri-tumour environment of ameloblastoma.
Materials and Methods: Sections were prepared for 18 formalin fixed paraffin-embedded blocks of ameloblastoma cases and stained with Azan trichrome stain according to the manufacturer's specification.
Results and Conclusions: The tumour areas were stained mostly brown, with the ameloblasts mainly marked as deep brown while the stellate reticulum-like region was light brown. The structures in the peri-tumour region were marked with different shades of blue. Azan trichrome staining was able to distinguish between the fibrous connective tissue and the stellate reticulum-like areas in 100% of the cases.
MiR144/451 expression is repressed by RUNX1 during megakaryopoiesis and disturbed by RUNX1/ETO
(2016)
Abstract: A network of lineage-specific transcription factors and microRNAs tightly regulates differentiation of hematopoietic stem cells along the distinct lineages. Deregulation of this regulatory network contributes to impaired lineage fidelity and leukemogenesis. We found that the hematopoietic master regulator RUNX1 controls the expression of certain microRNAs, of importance during erythroid/megakaryocytic differentiation. In particular, we show that the erythorid miR144/451 cluster is epigenetically repressed by RUNX1 during megakaryopoiesis. Furthermore, the leukemogenic RUNX1/ETO fusion protein transcriptionally represses the miR144/451 pre-microRNA. Thus RUNX1/ETO contributes to increased expression of miR451 target genes and interferes with normal gene expression during differentiation. Furthermore, we observed that inhibition of RUNX1/ETO in Kasumi1 cells and in RUNX1/ETO positive primary acute myeloid leukemia patient samples leads to up-regulation of miR144/451. RUNX1 thus emerges as a key regulator of a microRNA network, driving differentiation at the megakaryocytic/erythroid branching point. The network is disturbed by the leukemogenic RUNX1/ETO fusion product.
Author Summary: The regulatory network between transcription factors, epigenetic cofactors and microRNAs is decisive for normal hematopoiesis. The transcription factor RUNX1 is important for the establishment of a megakaryocytic gene expression program and the concomitant repression of erythroid genes during megakaryocytic differentiation. Gene regulation by RUNX1 is frequently disturbed by mutations and chromosomal translocations, such as the t(8;21) translocation, which gives rise to the leukemogenic RUNX1/ETO fusion protein. We found that RUNX1 regulates microRNAs, which are of importance at the megakaryocytic/erythroid branching point. Specifically, RUNX1 down-regulates expression of the microRNA cluster miR144/451 during megakaryocytic differentiation by changing the epigenetic histone modification pattern at the locus. We could show that miR451, one of the micorRNAs of the miR144/451 cluster, supports erythroid differentiation. We found that expression of miR451 is repressed by the RUNX1/ETO fusion protein, resulting in up regulation of miR451 target genes. Our data support the notion that RUNX1 suppresses the erythroid gene expression program including the erythroid microRNA miR451 and that the RUNX1/ETO fusion protein interferes with normal gene regulation by RUNX1.
Aims: To investigate real-world clinical and patient-related variables associated with initiating GLP-1 receptor agonist (GLP-1RA) treatment relative to initiation of other glucose-lowering therapies in type 2 diabetes (T2D) patients of primary care in Germany.
Methods: Data for 938 T2D patients who started therapy with a GLP-1RA within 823 practices of primary care throughout Germany were retrospectively analyzed (Disease Analyser: 01/2011–03/2014). 5,197 T2D patients who initiated other non-GLP-1RA antidiabetic therapies were selected as controls. Multivariate logistic regression analyses were applied to identify factors associated with GLP-1RA initiation in primary care.
Results: Mean age (SD) of GLP-1RA users was 57.8 (11.8) years (males: 55.5%) and the average BMI was 36.1 (6.7) kg/m2. 22.8% were in diabetologist care and 12.0% had private health insurance. In multivariate regression, choice of GLP-1RA therapy instead of a different glucose-lowering drug class was associated with obesity (odds ratio: 1.68; 95% CI: 1.34–2.10), private health insurance (2.42; 1.89–3.09), younger age (0.94; 0.93–0.95 per year), male sex (0.85; 0.73–0.99), diabetologist care (2.11; 1.73–2.57), and geographic practice location (East vs. West-Germany; 1.25; 1.05–1.49). Among co-medication, angiotensin II antagonists (increased) and non-steroidal antirheumatic agents (decreased) were related to GLP-1RA prescriptions (both p<0.001).
Conclusions: Consistent with German guidelines, GLP-1RA is mainly prescribed preferentially in T2D patients who are obese. GLP-1RA drugs were more frequently used than other options in privately health insured patients and in patients seeing a diabetologist.
Background: We conducted a phase I study with a granulocyte macrophage colony stimulating factor (GMCSF)-expressing oncolytic adenovirus, ONCOS-102, in patients with solid tumors refractory to available treatments. The objectives of the study were to determine the optimal dose for further use and to assess the safety, tolerability and adverse event (AE) profile of ONCOS-102. Further, the response rate and overall survival were evaluated as well as preliminary evidence of disease control. As an exploratory endpoint, the effect of ONCOS 102 on biological correlates was examined.
Methods: The study was conducted using a classic 3 + 3 dose escalation study design involving 12 patients. Patients were repeatedly treated intratumorally with ONCOS-102 plus daily low-dose oral cyclophosphamide (CPO). Tumor response was evaluated with diagnostic positron emission tomography (PET) and computed tomography (CT). Tumor biopsies were collected at baseline and after treatment initiation for analysis of immunological correlates. Peripheral blood mononuclear cells (PBMCs) were collected at baseline and during the study to assess antigen specificity of CD8+ T cells by interferon gamma (IFNγ) enzyme linked immunospot assay (ELISPOT).
Results: No dose limiting toxicity (DLT) or maximum tolerated dose (MTD) was identified for ONCOS-102. Four out of ten (40 %) evaluable patients had disease control based on PET/CT scan at 3 months and median overall survival was 9.3 months. A short-term increase in systemic pro-inflammatory cytokines and a prominent infiltration of TILs to tumors was seen post-treatment in 11 out of 12 patients. Two patients showed marked infiltration of CD8+ T cells to tumors and concomitant systemic induction of tumor-specific CD8+ T cells. Interestingly, high expression levels of genes associated with activated TH1 cells and TH1 type immune profile were observed in the post-treatment biopsies of these two patients.
Conclusions: ONCOS-102 is safe and well tolerated at the tested doses. All three examined doses may be used in further development. There was evidence of antitumor immunity and signals of clinical efficacy. Importantly, treatment resulted in infiltration of CD8+ T cells to tumors and up-regulation of PD-L1, highlighting the potential of ONCOS-102 as an immunosensitizing agent for combinatory therapies with checkpoint inhibitors.
Trial registration: NCT01598129. Registered 19/04/2012
The translation inhibitor and tumor suppressor Pdcd4 was reported to be lost in various tumors and put forward as prognostic marker in tumorigenesis. Decreased Pdcd4 protein stability due to PI3K-mTOR-p70S6K1 dependent phosphorylation of Pdcd4 followed by β-TrCP1-mediated ubiquitination, and proteasomal destruction of the protein was characterized as a major mechanism contributing to the loss of Pdcd4 expression in tumors. In an attempt to identify stabilizers of Pdcd4, we used a luciferase-based high-throughput compatible cellular assay to monitor phosphorylation-dependent proteasomal degradation of Pdcd4 in response to mitogen stimulation. Following a screen of approximately 2000 compounds, we identified 1,2-bis(4-chlorophenyl)disulfide as a novel Pdcd4 stabilizer. To determine an initial structure-activity relationship, we used 3 additional compounds, synthesized according to previous reports, and 2 commercially available compounds for further testing, in which either the linker between the aryls was modified (compounds 2–4) or the chlorine residues were replaced by groups with different electronic properties (compounds 5 and 6). We observed that those compounds with alterations in the sulfide linker completely lost the Pdcd4 stabilizing potential. In contrast, modifications in the chlorine residues showed only minor effects on the Pdcd4 stabilizing activity. A reporter with a mutated phospho-degron verified the specificity of the compounds for stabilizing the Pdcd4 reporter. Interestingly, the active diaryl disulfides inhibited proliferation and viability at concentrations where they stabilized Pdcd4, suggesting that Pdcd4 stabilization might contribute to the anti-proliferative properties. Finally, computational modelling indicated that the flexibility of the disulfide linker might be necessary to exert the biological functions of the compounds, as the inactive compound appeared to be energetically more restricted.
Abstract:
Snakebite is an important medical emergency in rural Nepal. Correct identification of the biting species is crucial for clinicians to choose appropriate treatment and anticipate complications. This is particularly important for neurotoxic envenoming which, depending on the snake species involved, may not respond to available antivenoms. Adequate species identification tools are lacking. This study used a combination of morphological and molecular approaches (PCR-aided DNA sequencing from swabs of bite sites) to determine the contribution of venomous and non-venomous species to the snakebite burden in southern Nepal. Out of 749 patients admitted with a history of snakebite to one of three study centres, the biting species could be identified in 194 (25.9%). Out of these, 87 had been bitten by a venomous snake, most commonly the Indian spectacled cobra (Naja naja; n = 42) and the common krait (Bungarus caeruleus; n = 22). When both morphological identification and PCR/sequencing results were available, a 100% agreement was noted. The probability of a positive PCR result was significantly lower among patients who had used inadequate “first aid” measures (e.g. tourniquets or local application of remedies). This study is the first to report the use of forensic genetics methods for snake species identification in a prospective clinical study. If high diagnostic accuracy is confirmed in larger cohorts, this method will be a very useful reference diagnostic tool for epidemiological investigations and clinical studies.
Author Summary:
Snakebite is an important medical problem in sub-tropical and tropical regions, including Nepal where tens of thousands of people are bitten every year. Snakebite can result in life-threatening envenoming, and correct identification of the biting species is crucial for care providers to choose appropriate treatment and anticipate complications. This paper explores a number of methods, including molecular techniques, to assist care providers in identifying the species responsible for bites in rural Nepal. Out of 749 patients with a history of snakebite, the biting species could be identified in 194 (25.9%). Out of these, 87 had been bitten by a venomous snake, most commonly cobras (n = 42) and kraits (n = 22). This study is the first to report the use of molecular techniques for snake species identification. The diagnostic accuracy of this method appears high but needs to be confirmed in larger studies.
Purpose: To evaluate the efficacy of the virtual reality training simulator Eyesi to prepare surgeons for performing pars plana vitrectomies and its potential to predict the surgeons’ performance.
Methods: In a preparation phase, four participating vitreoretinal surgeons performed repeated simulator training with predefined tasks. If a surgeon was assigned to perform a vitrectomy for the management of complex retinal detachment after a surgical break of at least 60 hours it was randomly decided whether a warmup training on the simulator was required (n = 9) or not (n = 12). Performance at the simulator was measured using the built-in scoring metrics. The surgical performance was determined by two blinded observers who analyzed the video-recorded interventions. One of them repeated the analysis to check for intra-observer consistency. The surgical performance of the interventions with and without simulator training was compared. In addition, for the surgeries with simulator training, the simulator performance was compared to the performance in the operating room.
Results: Comparing each surgeon’s performance with and without warmup trainingshowed a significant effect of warmup training onto the final outcome in the operating room. For the surgeries that were preceeded by the warmup procedure, the performance at the simulator was compared with the operating room performance. We found that there is a significant relation. The governing factor of low scores in the simulator were iatrogenic retinal holes, bleedings and lens damage. Surgeons who caused minor damage in the simulation also performed well in the operating room.
Conclusions: Despite the large variation of conditions, the effect of a warmup training as well as a relation between the performance at the simulator and in the operating room was found with statistical significance. Simulator training is able to serve as a warmup to increase the average performance.
Background and Objectives: Tick-borne encephalitis (TBE) still represents a considerable medical and health economic problem in Europe and entails a potential threat to travellers. The aim of this study was to characterise the conditions of severe TBE by precisely recording its clinical variants, the related neuroimaging features, and the variant-specific long-term outcome and by identifying predictors for severe courses.
Methods: A cohort of 111 TBE patients (median age 51, range 17–75 years; 42% females) was analysed prospectively. Data were acquired from the department of neurology, University Hospital Heidelberg, and the infectious diseases registry of the Robert-Koch institute Berlin. Neurological status was ascertained by protocol at admission and discharge and the degree of disability was scored using the modified RANKIN Scale (mRS; clinical score addressing neurological disability, range from 0, healthy to 6, dead) at admission and at follow-up. Follow-up examination was conducted by means of a telephone interview. To identify independent predictors for severe TBE and functional outcome, modelled logistic regression was performed. MRI changes were correlated with infection variants. To assess alpha-motor neuron injury patterns, we used high resolution magnetic resonance neurography (hrMRN). Analyses were performed at the Department of Neurology, University Hospital, University of Heidelberg from April 2004 through September 2014
Results: Acute course: 3.6% of patients died during the acute infection. All patients with a lethal course suffered from meningoencephaloradiculitis (MER, 14.4% of the cohort), which is associated with a significantly higher risk of requiring intensive care (p = 0.004) and mechanical ventilation (p<0.001) than menigoencephalitis (ME, 27.9% of the cohort). At admission, both MER and ME groups were severely affected, with the MER group having a statistically higher mRS score (median of 5 in the MER groups versus 4 in the ME group; p<0.001). Long-term outcome: outcome for MER was considerably worse (median mRS = 4) than for ME (mRS = 1, p<0.0001) and meningitis (mRS = 0, 57.7% of the cohort). Risk factors: advanced age (p<0.001) and male gender (p = 0.043) are independent risk factors for a severe infection course. Furthermore, we identified pre-existing diabetes mellitus (p = 0.024) as an independent risk factor for MER. In MER, alpha-motor neuron injury accounts for the poor prognosis confirmed by hrMRN.
Conclusion and Relevance: These data provide critical information for neurologists and other health professionals to use in evaluating TBEV patients who live in or travel to endemic areas. This information can be used to classify clinical presentation and estimate infection-associated complications and individual prognosis. Furthermore, the risk for severe, disabling infections in older patients should prompt general practitioners to recommend and encourage vaccination to those patients living in or travelling to endemic areas.
Epigenetic marks critically control gene expression and thus the cellular activity state. The functions of many epigenetic modifiers in the vascular system have not yet been studied. We screened for histone modifiers in endothelial cells and observed a fairly high expression of the histone plant homeodomain finger protein 8 (PHF8). Given its high expression, we hypothesize that this histone demethylase is important for endothelial cell function. Overexpression of PHF8 catalyzed the removal of methyl-groups from histone 3 lysine 9 (H3K9) and H4K20, whereas knockdown of the enzyme increased H3K9 methylation. Knockdown of PHF8 by RNAi also attenuated endothelial proliferation and survival. As a functional readout endothelial migration and tube formation was studied. PHF8 siRNA attenuated the capacity for migration and developing of capillary-like structures. Given the impact of PHF8 on cell cycle genes, endothelial E2F transcription factors were screened, which led to the identification of the gene repressor E2F4 to be controlled by PHF8. Importantly, PHF8 maintains E2F4 but not E2F1 expression in endothelial cells. Consistently, chromatin immunoprecipitation revealed that PHF8 reduces the H3K9me2 level at the E2F4 transcriptional start site, demonstrating a direct function of PHF8 in endothelial E2F4 gene regulation. Conclusion: PHF8 by controlling E2F4 expression maintains endothelial function.
Introduction: Interferon alpha (IFNα) is routinely used in the clinical practice for adjuvant systemic melanoma therapy. Understanding the molecular mechanism of IFNα effects and prediction of response in the IFNα therapy regime allows initiation and continuation of IFNα treatment for responder and exclusion of non-responder to avoid therapy inefficacy and side-effects. The transporter protein associated with antigen processing-1 (TAP1) is part of the MHC class I peptide-loading complex, and important for antigen presentation in tumor and antigen presenting cells. In the context of personalized medicine, we address this potential biomarker TAP1 as a target of IFNα signalling.
Results: We could show that IFNα upregulates TAP1 expression in peripheral blood mononuclear cells (PBMCs) of patients with malignant melanoma receiving adjuvant high-dose immunotherapy. IFNα also induced expression of TAP1 in mouse blood and tumor tissue and suppressed the formation of melanoma metastasis in an in vivo B16 tumor model. Besides its expression, TAP binding affinity and transport activity is induced by IFNα in human monocytic THP1 cells. Furthermore, our data revealed that IFNα clearly activates phosphorylation of STAT1 and STAT3 in THP1 and A375 melanoma cells. Inhibition of Janus kinases abrogates the IFNα-induced TAP1 expression. These results suggest that the JAK/STAT pathway is a crucial mediator for TAP1 expression elicited by IFNα treatment.
Conclusion: We suppose that silencing of TAP1 expression provides tumor cells with a mechanism to escape cytotoxic T-lymphocyte recognition. The observed benefit of IFNα treatment could be mediated by the shown dual effect of TAP1 upregulation in antigen presenting cells on the one hand, and of TAP1 upregulation in ‘silent’ metastatic melanoma cells on the other hand. In conclusion, this work contributes to a better understanding of the mode of action of IFNα which is essential to identify markers to predict, assess and monitor therapeutic response of IFNα treatment in the future.
Introduction: The Helicopter Emergency Medical Service (HEMS) was established for the prehospital trauma care of patients. Improved rescue times and increased coverage areas are discussed as specific advantages of HEMS. We recently found evidence that HEMS exerts beneficial effects on outcomes for severely injured patients. However, it still remains unknown which group of trauma patients might benefit most from HEMS rescue. Consequently, the unique aim of this study was to reveal which patients might benefit most from HEMS rescue.
Methods: Trauma patients (ISS ≥9) primarily treated by HEMS or ground emergency medical services (GEMS) between 2002 and 2012 were analysed using the TraumaRegister DGU. A multivariate regression analysis was used to reveal the survival benefit between different trauma populations.
Results: The study included 52 281 trauma patients. Of these, 68.8% (35 974) were rescued by GEMS and 31.2% (16 307) by HEMS. HEMS patients were more severely injured compared to GEMS patients (ISS: HEMS 24.8±13.5 vs. GEMS 21.7±18.0) and more frequently suffered traumatic shock (SBP sys <90mmHg: HEMS 18.3% vs. GEMS 14.8%). However, logistic regression analysis revealed that HEMS rescues resulted in an overall survival benefit compared to GEMS (OR 0.81, 95% CI [0.75–0.87], p<0.001, Nagelkerke's R squared 0.526, area under the ROC curve 0.922, 95% CI [0.919–0.925]). Analysis of specific subgroups demonstrated that patients aged older than 55 years (OR 0.62, 95% CI [0.50–0.77]) had the highest survival benefit after HEMS treatment. Furthermore, HEMS rescue had the most significant impact after ‘low falls’ (OR 0.68, 95% CI [0.55–0.84]) and in the case of minor severity injuries (ISS 9–15) (OR 0.66, 95% CI [0.49–0.88]).
Conclusions: In general, trauma patients benefit from HEMS rescue with in-hospital survival as the main outcome parameter. Focusing on special subgroups, middle aged and older patients, low-energy trauma, and minor severity injuries had the highest survival benefit when rescued by HEMS. Further studies are required to determine the potential reasons of this benefit.
Pathogenicity of many microbes relies on their capacity to resist innate immunity, and to survive and persist in an immunocompetent human host microbes have developed highly efficient and sophisticated complement evasion strategies. Here we show that different human pathogens including Gram-negative and Gram-positive bacteria, as well as the fungal pathogen Candida albicans, acquire the human terminal complement regulator vitronectin to their surface. By using truncated vitronectin fragments we found that all analyzed microbial pathogens (n = 13) bound human vitronectin via the same C-terminal heparin-binding domain (amino acids 352–374). This specific interaction leaves the terminal complement complex (TCC) regulatory region of vitronectin accessible, allowing inhibition of C5b-7 membrane insertion and C9 polymerization. Vitronectin complexed with the various microbes and corresponding proteins was thus functionally active and inhibited complement-mediated C5b-9 deposition. Taken together, diverse microbial pathogens expressing different structurally unrelated vitronectin-binding molecules interact with host vitronectin via the same conserved region to allow versatile control of the host innate immune response.
Introduction: For resectable soft tissue sarcoma (STS), radical surgery, usually combined with radiotherapy, is the mainstay of treatment and the only potentially curative modality. Since surgery is often complicated by large tumour size and extensive tumour vasculature, preoperative treatment strategies with the aim of devitalising the tumour are being explored. One option is treatment with antiangiogenic drugs. The multikinase inhibitor pazopanib, which possesses pronounced antiangiogenic effects, has shown activity in metastatic and unresectable STS, but has so far not been tested in the preoperative setting.
Methods and analysis: This open-label, multicentre phase II window-of-opportunity trial assesses pazopanib as preoperative treatment of resectable STS. Participants receive a 21-day course of pazopanib 800 mg daily during wait time for surgery. Major eligibility criteria are resectable, high-risk adult STS of any location, or metachronous solitary STS metastasis for which resection is planned, and adequate organ function and performance status. The trial uses an exact single-stage design. The primary end point is metabolic response rate (MRR), that is, the proportion of patients with >50% reduction of the mean standardised uptake value (SUVmean) in post-treatment compared to pre-treatment fluorodeoxyglucose positron emission tomography CT. The MRR below which the treatment is considered ineffective is 0.2. The MRR above which the treatment warrants further exploration is 0.4. With a type I error of 5% and a power of 80%, the sample size is 35 evaluable patients, with 12 or more responders as threshold. Main secondary end points are histopathological and MRI response, resectability, toxicity, recurrence-free and overall survival. In a translational substudy, endothelial progenitor cells and vascular epithelial growth factor receptor are analysed as potential prognostic and predictive markers.
Ethics and dissemination: Approval by the ethics committee II, University of Heidelberg, Germany (2012-019F-MA), German Federal Institute for Drugs and Medical Devices (61-3910-4038155) and German Federal Institute for Radiation Protection (Z5-22463/2-2012-007).
Trial registration number: NCT01543802, EudraCT: 2011-003745-18; Pre-results.
Effect of M3 muscarinic acetylcholine receptor deficiency on collagen antibody-induced arthritis
(2016)
Background: There is increasing evidence that the non-neuronal cholinergic system might be of importance for the pathology of rheumatoid arthritis. The role of M3 muscarinic acetylcholine receptor (M3R) in this regard has, however, not been investigated to date. Thus, in the present study we analyzed if M3R deficiency might have a protective effect on experimentally induced arthritis.
Methods: Collagen antibody-induced arthritis (CAIA) was evoked in M3R-deficient (M3R −/− ) mice and wild-type (WT) littermates. Severity of arthritis was assessed by scoring of paw swelling. The joints of arthritic and nonarthritic animals were analyzed for histopathological changes regarding synovial tissue, cartilage degradation and bone destruction. Further, gene expression analysis of respective markers was performed. Systemic and local inflammatory response was determined by flow cytometry and immunohistochemistry for leukocytes as well as mRNA and protein measurements for pro-inflammatory cytokines and chemokines.
Results: In arthritic M3R −/− mice the number of leukocytes, specifically neutrophils, was enhanced even though clinical arthritis score was not significantly different between WT and M3R −/− mice with CAIA. In M3R −/− mice, levels of neutrophil chemoattractant chemokine C-X-C-motif ligand 2 (CXCL2) as well as the pro-inflammatory cytokine interleukin-6 were already strongly increased in mice with low arthritis score, whereas WT mice only showed prominent expression of these markers when reaching high arthritis scores. Furthermore, arthritic M3R −/− mice displayed a stronger degradation of collagen II in the articular cartilage and, most strikingly, histopathological evaluation revealed more severe bone destruction in arthritic mice with M3R deficiency compared to WT littermates. Moreover, in M3R −/− mice, gene expression of markers for bone degradation (matrix metalloproteinase 13, cathepsin K and receptor activator of nuclear factor-κB ligand) was already increased in mice with low arthritis score.
Conclusions: Taken together, the present study shows that while M3R −/− mice were not protected from CAIA, they had a tendency toward a higher inflammatory response after arthritis induction than WT mice. Further, arthritis-induced joint destruction was significantly stronger in mice with M3R deficiency, indicating that stimulation of M3R might have protective effects on arthritis.